FDA's Final IND Guidance Has Industry On Edge: What Happens Next?
This article was originally published in The Rose Sheet
It remains to be seen how industry responds to FDA's newly reissued final guidance advising firms to file Investigational New Drug applications for studies exploring would-be cosmetics' structure/function benefits, and how rigorously the agency enforces its position. Attorney Paul Hyman speculates that FDA could rely on INDs to reinforce its authority in the context of warning letters issued to cosmetics firms for unapproved drug claims.
You may also be interested in...
FDA Rulemaking Could Be Imminent On Investigational New Drug Requirements For Cosmetics, Dietary Supplements
Are investigational new drug applications required for clinical trials conducted by cosmetics companies to evaluate potential body structure/function effects, or clinical studies undertaken by dietary supplement companies to support a new or expanded health claim? FDA said they are in final guidance reissued in late 2015 and now has rulemaking planned on the subject that could commence this month.
Pharmagel's name and billing as "pharmaceutical grade anti-aging skin care" may have drawn FDA's attention, but benefits cited in the agency's warning letter – including collagen- and elastic-building claims – are consistent with FDA's enforcement action against other companies so far in 2015.
Attorney Steven Shapiro, a partner at Ullman, Shapiro & Ullman, LLP, offers perspective on what he considers some of the biggest challenges cosmetics companies face in the current regulatory and legal landscape, specifically when it comes to crafting claims. Story features audio clips from the attorney’s interview with “The Rose Sheet.”